血浆和肽素与1型和2型糖尿病下肢截肢风险
在4个队列(1型糖尿病710例、2型糖尿病4553例)中评估基线血浆和肽素与随访期下肢截肢(LEA)风险的关联。1型糖尿病中随和肽素三分位升高LEA累积发生率分别为3.9%、3.3%、10.0%(P=0.002),2型糖尿病为1.1%、2.9%、3.6%(P<0.0001),Cox回归显示和肽素与LEA独立相关。
要点
- 基线血浆和肽素升高与1型和2型糖尿病下肢截肢累积发生率增加相关
- 1型糖尿病中log[和肽素]每增加1个SD,LEA风险HR为1.89(95%CI 1.28-2.82)
- 和肽素或有助于识别下肢截肢高风险患者
核心结论
- 基线血浆和肽素与1型和2型糖尿病队列中下肢截肢的累积发生率相关,可能有助于识别LEA风险患者。
研究设计与样本
- 四项队列研究:1型糖尿病为GENESIS(n=503)和GENEDIAB(n=207),2型糖尿病为DIABHYCAR(n=3,101)和SURDIAGENE(n=1,452)。
- 基线血浆和肽素采用免疫发光测定法检测,随访中位时间5至10年。
- 合并1型糖尿病队列n=710,合并2型糖尿病队列n=4,553。
主要发现
- 1型糖尿病队列按基线血浆和肽素三分位(TER1、TER2、TER3)的LEA累积发生率分别为3.9%、3.3%、10.0%(P=0.002)。
- 1型糖尿病中log[和肽素]每增加1个SD的LEA风险HR为1.89(95%CI 1.28-2.82),P=0.002。
- 2型糖尿病队列LEA累积发生率为1.1%(TER1)、2.9%(TER2)、3.6%(TER3),P<0.0001。
- 2型糖尿病中log[和肽素]每增加1个SD的LEA风险HR为1.42(95%CI 1.15-1.74),P=0.001。
- 2型糖尿病队列中下肢血运重建的HR为1.20(95%CI 1.03-1.39),P=0.02。
临床怎么用
- 对1型或2型糖尿病患者可考虑检测基线血浆和肽素,以辅助识别下肢截肢高风险人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes is the leading cause of nontraumatic lower-extremity amputations (LEAs). Identification of patients with foot ulcers at risk for amputation remains clinically challenging. Plasma copeptin, a surrogate marker of vasopressin, is associated with the risk of cardiovascular and renal complications in diabetes. RESEARCH DESIGN AND METHODS: We assessed the association between baseline plasma copeptin and risk of LEA during follow-up in four cohorts of people with type 1 (GENESIS, n = 503, and GENEDIAB, n = 207) or type 2 diabetes (DIABHYCAR, n = 3,101, and SURDIAGENE, n = 1,452) with a median duration of follow-up between 5 and 10 years. Copeptin concentration was measured in baseline plasma samples by an immunoluminometric assay. RESULTS: In the pooled cohorts with type 1 diabetes (n = 710), the cumulative incidence of LEA during follow-up by increasing tertiles (tertile 1 [TER1], TER2, and TER3) of baseline plasma copeptin was 3.9% (TER1), 3.3% (TER2), and 10.0% (TER3) (P = 0.002). Cox regression analyses confirmed the association of copeptin with LEA: hazard ratio (HR) for 1 SD increment of log[copeptin] was 1.89 (95% CI 1.28-2.82), P = 0.002. In the pooled cohorts of type 2 diabetes (n = 4,553), the cumulative incidence of LEA was 1.1% (TER1), 2.9% (TER2), and 3.6% (TER3) (P < 0.0001). In Cox regression analyses, baseline plasma copeptin was significantly associated with LEA: HR for 1 SD increment of log[copeptin] was 1.42 (1.15-1.74), P = 0.001. Similar results were observed in the cohort with type 2 diabetes for lower-limb revascularization (HR 1.20 [95% CI 1.03-1.39], P = 0.02). CONCLUSIONS: Baseline plasma copeptin is associated with cumulative incidence of LEA in cohorts of people with both type 1 and type 2 diabetes and may help to identify patients at risk for LEA.
引用
- Potier L, Roussel R, Marre M, et al. Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care. 2019. PMID: 31582427. doi:10.2337/dc19-1062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。